Pulmotech MAA

PULMOTECH MAA- albumin aggregated injection, powder, lyophilized, for suspension
Curium US LLC

1 INDICATIONS AND USAGE

PULMOTECH MAA, after radiolabeling with technetium-99m, is indicated for:

  • Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients.
  • Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults.

2 DOSAGE AND ADMINISTRATION

The number of particles available per dose of Technetium Tc 99m Albumin Aggregated Injection will vary depending on the physical decay of technetium-99m that has occurred. The number of particles in any dose and volume to be administrated may be calculated as follows:

2.1 Radiation Safety – Drug Handling

After radiolabeling of PULMOTECH MAA, the vial contains Technetium Tc 99m Albumin Aggregated Injection. Handle Technetium Tc 99m Albumin Aggregated Injection with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions ( 5.4)]. Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Technetium Tc 99m Albumin Aggregated Injection.

Radiopharmaceuticals should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

2.2 Patient Preparation

Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to administration of Technetium Tc 99m Albumin Aggregated Injection and to continue to drink and void frequently following administration to reduce radiation exposure [see Warnings and Precautions ( 5.4)].

2. 3 Recommended Dosage for Lung Perfusion Scintigraphy

Adult Patients

The recommended activity for lung perfusion scintigraphy in adult patients is 37 MBq to 148 MBq (1 mCi to 4 mCi) by intravenous injection.

The range of particle numbers per single injection should be 200,000 to 700,000 with the recommended number of approximately 350,000. Depending on the activity added and volume of the final radiolabeled product, the volume of the dose may vary from 0.2 mL to 1.9 mL.

The number of particles available per dose of Technetium Tc 99m Albumin Aggregated Injection will vary depending on the physical decay of technetium-99m that has occurred. The number of particles in any dose and volume to be administrated may be calculated as follows:

The number of particles available per dose of Technetium Tc 99m Albumin Aggregated Injection will vary depending on the physical decay of technetium-99m that has occurred. The number of particles in any dose and volume to be administrated may be calculated as follows:
(click image for full-size original)

Where:

Va = volume to be administered in mL

D = desired activity to be administered in MBq (mCi)

C = concentration at calibration time of Sodium Pertechnetate Tc 99m Injection to be added to the reaction vial in MBq/mL (mCi/mL)

Fr = fraction of Technetium-99m remaining after the time of calibration from Table 6 [see Description ( 11.3)]

P = number of particles in dose to be administered

Va = volume to be administered in mL

VTc = volume of Sodium Pertechnetate Tc 99m Injection added to reaction vial in mL

N = number of particles per vial. The number of particles per vial for the lot is located on the vial label.

Pediatric Patients Aged 4 Weeks and Older

The recommended activity for lung perfusion scintigraphy in pediatric patients aged 4 weeks and older by intravenous injection is based on body weight and ranges from 0.925 MBq/kg to 1.85 MBq/kg (0.025 mCi/kg to 0.05 mCi/kg). The minimum recommended dose for lung perfusion scintigraphy in this age is 7.4 MBq (0.2 mCi).

The number of particles will vary with age and body weight of the pediatric patient. Particle numbers administered in four different age and weight categories are shown in Table 1.

Table 1 – Particle Numbers Administered in Four Different Age and Weight Categories of Pediatric Patients Receiving Maximum Recommended Activity of Technetium Tc 99m Albumin Aggregated Injection for Lung Perfusion Scintigraphy
Age15 years10 years5 years1 year
Weight (kg)5533.520.312.1
Maximal recommended activityMBq 103.6mCi 2.8MBq 62.9mCi 1.7MBq 37mCi 1MBq 22.2mCi 0.6
Range of particlesadministered200,000 to700,000200,000 to300,000200,000 to300,00050,000 to150,000

Pediatric Patients Aged Less Than 4 Weeks (Neonates)

The recommended activity for lung perfusion scintigraphy in neonates by intravenous injection is 7.4 MBq to 18.5 MBq (0.2 mCi to 0.5 mCi). The number of particles in neonates for lung perfusion scintigraphy ranges from 10,000 to 50,000. Use the lowest possible number of particles for neonates.

2.4 Recommended Dosage for Peritoneo veno us Shunt Scintigraphy in Adults

The recommended activity for peritoneovenous shunt scintigraphy in adult patients is 37 MBq to 111 MBq (1 mCi to 3 mCi) by intraperitoneal injection and the number of particles per single injection should be 200,000 to 700,000 with the recommended number of approximately 350,000. Depending on the activity added and volume of the final radiolabeled product, the volume of the dose may vary from 0.2 mL to 1.9 mL. For calculation of the number of particles to be administered, see Recommended Dosage for Lung Perfusion Scintigraphy in Adult Patients [see Dosage and Administration ( 2.3)]. Assure uniform mixing with peritoneal fluid.

Alternatively, administer the drug by percutaneous transtubal injection. The recommended activity for percutaneous transtubal administration in adult patients is 12 MBq to 37 MBq (0.3 mCi to 1 mCi) in a volume not to exceed 0.5 mL.

2. 5 Directions for Drug Preparation and Handling

Procedural Precautions

  • Perform all transfer and vial stopper entries using aseptic techniques.
  • Wear waterproof gloves during the entire preparation procedure and during subsequent patient dose withdrawals from the PULMOTECH MAA vial.
  • Make all transfers of Sodium Pertechnetate Tc 99m Injection during the preparation procedure with an adequately shielded syringe.
  • Keep the prepared Technetium Tc 99m Albumin Aggregated Injection in the dispensing vial shield described below (with cap in place) during the useful life of the radioactive preparation. Make all withdrawals and injections of the Technetium Tc 99m Albumin Aggregated Injection with an adequately shielded syringe.

Procedure for the Preparation, Storage,and Handling of Technetium Tc 99m Albumin Aggregated Injection

  1. If PULMOTECH MAA reaction vials are stored in the refrigerator, remove a vial and allow the contents to come to room temperature for approximately 5 minutes.
  2. Remove the protective cap from the reaction vial and swab the rubber septum with an alcohol swab or a suitable bacteriostatic agent to disinfect the surface.
  3. Place the vial in a suitable dispensing vial shield fitted with a shielded cap.
  4. Calculate the amount of Sodium Pertechnetate Tc 99m Injection (2 mL to 13 mL) to be added to the reaction vial. In choosing the amount of Sodium Pertechnetate Tc 99m Injection to be used in the preparation of Technetium Tc 99m Albumin Aggregated Injection ensure that the radioactive dose will contain the desired number of macroaggregated albumin (MAA) particles, while taking into account the number of patients, administered activity, and radioactive decay. The recommended maximum activity of Sodium Pertechnetate Tc 99m Injection to be added to the reaction vial is 6.85 GBq (185 mCi). Calculate the amount of radioactivity per vial required to be added to maintain the number of particles per dose within a recommended range, for adults 200,000 to 700,000 and for pediatric patients as per Table 1 [see Dosage and Administration ( 2.3, 2.4) ] .
  5. After adding Sodium Pertechnetate Tc 99m Injection to the reaction vial in the dispensing vial shield (with cap in place), mix the contents by agitation and allow to stand for a minimum of 15 minutes at room temperature. During or prior to addition of Sodium Pertechnetate Tc 99m Injection do not vent the reaction vial. Once prepared the product will have a turbid white appearance.
  6. Assay the product in a suitable dose calibrator and record the total activity of Technetium Tc 99m Albumin Aggregated Injection, total volume, number of MAA particles, radioactive concentration, time and date of preparation, onto the radioassay information label and attach it to the dispensing vial shield. 0.9% Sodium Chloride Injection, USP may be used as a diluent for the radiolabeled product to achieve the desired number of particles and radioactivity.
  7. Prior to withdrawing a dose, gently agitate the contents of the radiolabeled PULMOTECH MAA vial to resuspend any settled technetium Tc 99m albumin aggregated particles. Failure to mix the reaction vial contents adequately before use may result in a non-homogenous suspension with a resulting non-uniform distribution of radioactivity in the lung. Since the vials contain nitrogen to prevent oxidation of the complex, the vials should not be vented. If repeated withdrawals are made from the vial, the contents should not be replaced with air.
  8. Store the radiolabeled PULMOTECH MAA in the dispensing vial shield in a refrigerator at 2°C to 8°C (36°F to 46°F). Use within 18 hours from the time of radiolabeling. Dispose unused radiolabeled PULMOTECH MAA in compliance with appropriate regulations.

Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.